Tetra offers regulatory expertise to develop COVID-19 solutions
April 8, 2020 By Grow Opportunity staff
Tetra Bio-Pharma Inc. is offering its expertise in regulatory affairs and quality assurance to support Canadian businesses seeking Health Canada approval for specific products used to combat the ongoing COVID-19 pandemic.
“COVID-19 is unprecedented in our lifetime and calls for an unprecedented response from all of us,” says Tetra Bio-Pharma CEO and CRO, Dr. Guy Chamberland, in a statement.
Tetra has a staff of 30 experts in preparing and filing applications for medical devices and drugs to regulators like Health Canada and FDA. Tetra also boasts experience in international requirements for drugs and medical devices.
“Helping these entrepreneurs secure approvals and avoid unnecessary delays in doing so may help save lives, which is why we support these efforts at 100 per cent,” said Chamberland.
Tetra Bio-Pharma is a biopharmaceutical company focused on cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program.
Print this page